The link between frailty and chronic disease development; Atripla’s long-term efficacy; the dangers of restrictive eligibility criteria for hepatitis C treatment; nicotine metabolism rates in people living with HIV.
After years of anecdotes and speculation, harm reduction and pharma watchdog advocates have data to back claims that the spike in opioid deaths in the U.S. can be tied to pharmaceutical companies marketing highly addictive opioids to doctors.
E/C/F/TAF viability for dialysis patients; TAF safety following renal damage; mental health needs for American Indians; parenting desires of people with HIV.
Our series on mentor-mentee researchers continues with Ellen Eaton, M.D., and Kelsie Dodson, with the University of Alabama at Birmingham.
Cholesterol guidelines may underestimate statin value; shifting from Ryan White CARE Act to Affordable Care Act coverage; HCV seroconversion and CD4 count suppression; HCV reinfection odds by risk group.
Unmet subsistence needs and clinical outcomes; finding HIV treatment success alongside quality-of-life issues; the potential value of facility-level HIV care continuum data; stimulant use and viral suppression.
We walk you through the most recent updates to official guidelines issued by the U.S. Department of Health and Human Services on the treatment and care of people living with HIV.
The most popular form of long-acting HIV treatment; telehealth for PrEP uptake among young MSM of color; PrEP awareness and usage among Rhode Island women; assessing cognitive benefits of switching off of efavirenz.
The impact of stigma on cognitive performance; risk factor dissonance among young black MSM; pregnancy and the HIV care continuum; new data on pediatric raltegravir use.
Curt G. Beckwith, M.D., and Sugi Min, his mentee, discuss their clinical research focused on improving the diagnosis, treatment, and longitudinal care of HIV infection among substance users, particularly those in the criminal justice system.